BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Jordan S ShafranNaser JafariAllison N CaseyBalázs GyőrffyGerald V DenisPublished in: Prostate cancer and prostatic diseases (2020)
Many relapsed/refractory tumors share a neuroendocrine transcriptional signature that had been relatively rare until highly successful antiandrogen drugs like abiraterone and enzalutamide came into widespread use. New therapeutic targets must therefore be developed. Our results identify key EMT genes regulated by BRD4, and offers a novel druggable target to treat mCRPC. BRD4-selective protein degraders offer a promising next generation approach to treat the emerging forms of chemoresistance in advanced prostate cancer.
Keyphrases
- prostate cancer
- epithelial mesenchymal transition
- transcription factor
- radical prostatectomy
- transforming growth factor
- signaling pathway
- acute lymphoblastic leukemia
- genome wide identification
- acute myeloid leukemia
- gene expression
- diffuse large b cell lymphoma
- multiple myeloma
- genome wide
- hodgkin lymphoma
- binding protein
- dna binding
- amino acid
- protein protein
- dna methylation
- heat shock
- heat shock protein